rintatolimod   Click here for help

GtoPdb Ligand ID: 14713

Synonyms: Ampligen | Atoven | Poly I: Poly C12U
Immunopharmacology Ligand
Compound class: Nucleic acid
Comment: Rintatolimod is a double-stranded RNA oligonucleotide that is intended to act as a Toll-like receptor 3 (TLR3) agonist [1].

Full sequence is:
poly[5')-inosinylyl-(3'→] duplex with poly[dodecakis[3')-cytidylyl- (5'→]3')-uridylyl-(5'→], which is similar to prototypical RNA poly I:C.
No information available.
Summary of Clinical Use Click here for help
Rintatolimod (Ampligen®) was approved in Canada in 1997 as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), but this was later rescinded, with prescription restricted within a Special Use Program. The drug was granted orphan drug status by the EU EMA in 2000, for ME/CFS. It may be approved for this indication in Argentina, but we have been unable to verify this.
In October 2026, rintatolimod was in active clinical trials to evaluate safety and efficacy as an immuno-oncology therapeutic that is intended to reprogram the local tumour microenvironment to mount an anti-tumour immune response [3,8]. Rintatolimod was also evaluated as a treatment for long-COVID [9], and for antiviral activity in HIV infection [2,7].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07634094 Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Phase 2 Interventional University of Pittsburgh
NCT05927142 Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy Phase 1/Phase 2 Interventional Erasmus Medical Center
NCT00215800 The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome Phase 3 Interventional AIM ImmunoTech Inc. 5-6